Alto Neuroscience Inc (ANRO)
Alto Neuroscience, Inc. is a clinical-stage biopharmaceutical company listed on the NYSE under the ticker ANRO. Headquartered in Mountain View, California, the company was incorporated in 2019 and focuses on developing therapies for central nervous system and neuropsychiatric conditions. Its pipeline includes ALTO-100, which is in a Phase 2b trial for bipolar depression; ALTO-300, a small-molecule melatonergic agonist and serotonergic antagonist in Phase 2b testing for major depressive disorder; and ALTO-101, a phosphodiesterase 4 inhibitor in Phase 2 proof-of-concept studies for cognitive impairment associated with schizophrenia. The company is also advancing ALTO-203 for major depressive disorder with higher levels of anhedonia, ALTO-202 for major depressive disorder, and ALTO-208 for patients with Parkinson’s disease.
Jump directly to the stock analysis sections supported by the latest available data.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Dividend Yield | Next Earnings Date | Price-to-Book Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NYSE-ANRO
|
$28.94
|
-4.4% Downside
|
Fair
|
$38.38
|
26.8% Upside
|
Undervalued
|
Fair
|
0.0%
|
November 11, 2026
|
5.4x
|
1.188 B
|
967.4 M
|
1.9%
|
75.6%
|
19.5
|
81.7%
|
